Harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy

Tal I. Arnon*, Gal Markel, Ahuva Bar-Ilan, Jacob Hanna, Eyal Fima, Fabrice Benchetrit, Ruth Galili, Adelheid Cerwenka, Daniel Benharroch, Netta Sion-Vardy, Angel Porgador, Ofer Mandelboim

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


The natural cytotoxic receptors (NCRs) are a unique set of activating proteins expressed mainly on the surface of natural killer (NK) cells. The NCRs, which include three members; NKp46, NKp44 and NKp30, are critically involved in NK cytotoxicity against different targets, including a wide range of tumor cells derived from various origins. Even though the tumor ligands of the NCRs have not been identified yet, the selective manner by which these receptors target tumor cells may provide an excellent basis for the development of novel anti-tumor therapies. To test the potential use of the NCRs as anti-tumor agents, we generated soluble NCR-Ig fusion proteins in which the constant region of human IgG1 was fused to the extracellular portion of the receptor. We demonstrate, using two different human prostate cancer cell lines, that treatment with NKp30-Ig, dramatically inhibits tumor growth in vivo. Activated macrophages were shown to mediate an ADCC response against the NKp30-Ig coated prostate cell lines. Finally, the Ig fusion proteins were also demonstrated to discriminate between benign prostate hyperplasia and prostate cancer. This may provide a novel diagnostic modality in the difficult task of differentiating between these highly common pathological conditions.

Original languageAmerican English
Article numbere2150
JournalPLoS ONE
Issue number5
StatePublished - 14 May 2008


Dive into the research topics of 'Harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy'. Together they form a unique fingerprint.

Cite this